BENACTYZINE

First approved in 1957

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H25NO3
Molecular Weight	327.4174
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN(CC)CCOC(=O)C(O)(C1=CC=CC=C1)C2=CC=CC=C2

InChI

InChIKey=IVQOFBKHQCTVQV-UHFFFAOYSA-N

InChI=1S/C20H25NO3/c1-3-21(4-2)15-16-24-19(22)20(23,17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,23H,3-4,15-16H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C20H25NO3
Molecular Weight	327.4174
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3683366 | https://www.ncbi.nlm.nih.gov/pubmed/13673692 | https://www.ncbi.nlm.nih.gov/pubmed/13597010

Benactyzine, an anticholinergic drug, had been used as an antidepressant in the treatment of depression and associated anxiety. It is no longer used in medicine due to its ineffectiveness but is widely used in scientific research. Benactyzine is a muscarinic antagonist which also inhibits the nicotinic acetylcholine receptor.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor 162 Target ID: CHEMBL2094109 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3683366	Antagonist 2849
Nicotinic acetylcholine receptor 10 Target ID: Nicotinic acetylcholine receptor Sources: https://www.ncbi.nlm.nih.gov/pubmed/3683366	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Depression 240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/5337279 https://www.ncbi.nlm.nih.gov/pubmed/20894073	Primary		Approved 8583	Deprol Approved Use treatment of depression
Anxiety 275 Sources: https://www.netdoktor.at/medikamente/anxiolit-plus-dragees-273008	Primary		Approved 8583	Anxiolit plus Approved Use Anxiety states of tension and excitement change of symptoms discomfort of the gastrointestinal tract, the cardiovascular system and the urinary tract due to psychological causes (psychovegetative complaints)

Doses

Dose	Population	Adverse events
1300 mg single, oral Overdose Dose: 1300 mg Route: oral Route: single Dose: 1300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/5699594	unknown Health Status: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/5699594	Disc. AE: Psychosis... AEs leading to discontinuation/dose reduction: Psychosis Sources: https://pubmed.ncbi.nlm.nih.gov/5699594
200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/5699594	healthy Health Status: healthy Sources: https://pubmed.ncbi.nlm.nih.gov/5699594	Disc. AE: Delirium... AEs leading to discontinuation/dose reduction: Delirium (severe) Sources: https://pubmed.ncbi.nlm.nih.gov/5699594

AEs

AE	Significance	Dose	Population
Psychosis	Disc. AE	1300 mg single, oral Overdose Dose: 1300 mg Route: oral Route: single Dose: 1300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/5699594	unknown Health Status: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/5699594
Delirium	severe Disc. AE	200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/5699594	healthy Health Status: healthy Sources: https://pubmed.ncbi.nlm.nih.gov/5699594

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MATE1 415

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
MATE1 416	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27418674/	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY547289	https://www.001chemical.com/chem/302-40-9
Aurora Fine Chemicals LLC	A17.406.394	http://online.aurorafinechemicals.com/info?ID=A17.406.394
Aurora Fine Chemicals LLC	K05.594.650	http://online.aurorafinechemicals.com/info?ID=K05.594.650
ChemBridge	5177085	http://www.hit2lead.com/search.asp?db=SC&ids=5177085
ChemMol	49426858	http://www.chemmol.com/chemmol/49426858.html
ChemMol	99068629	http://www.chemmol.com/chemmol/99068629.html
Chemspace	CSSS00015277072	https://chem-space.com/CSSS00015277072
mcule	MCULE-2668849266	https://mcule.com/MCULE-2668849266/
Molcore	MC547289	https://www.molcore.com/product/302-40-9
OChem	12166	http://www.ocheminc.com/index.php?act=psearch&pid=302B409
Smolecule	S520728	http://www.smolecule.com/products/s520728
THE BioTek	bt-261322	https://www.thebiotek.com/product/inhibitors/bt-261322
Yuhao Chemical	LL0667	http://www.chemyuhao.com/302-40-9.html

PubMed

Title	Date	PubMed
[Tolerance of prostate biopsy with use of local anesthesia and benzodiazepines: a randomized, prospective study].	2010-01	20223132
Paraoxon attenuates vascular smooth muscle contraction through inhibiting Ca2+ influx in the rabbit thoracic aorta.	2010	20445738
Sexual function in adult male rats after prenatal modulation of the cholinergic system.	2009-06	19430975
Chemical aspects of pharmacological prophylaxis against nerve agent poisoning.	2009	19689278
Therapy against organophosphate poisoning: the importance of anticholinergic drugs with antiglutamatergic properties.	2008-10-15	18680758
The present approaches to the development of prophylactic and therapeutic antidotes against nerve agents.	2008-06	21218100
Antiparkinson drugs used as prophylactics for nerve agents: studies of cognitive side effects in rats.	2008-06	18384867
[The sexual function of mature rat males after prenatal modulation of cholinergic system].	2008-05	18669363
Role of the cholinergic mechanisms of the ventrolateral preoptic area of the hypothalamus in regulating the state of sleep and waking in pigeons.	2008-03	18264771
Efficacy of antidotal treatment against sarin poisoning: the superiority of benactyzine and caramiphen.	2008-02-15	18320638
Anticonvulsant efficacy of drugs with cholinergic and/or glutamatergic antagonism microinfused into area tempestas of rats exposed to soman.	2008-02	17710542
Protective effect of reversible cholinesterase inhibitors (tacrine, pyridostigmine) and eqbuche against VX poisoning and brain acetylcholinesterase inhibition in rats.	2008	19453088
Therapeutic and neuroprotective efficacy of pharmacological pretreatment and antidotal treatment of acute tabun or soman poisoning with the emphasis on pretreatment drug PANPAL.	2006-12	17265682
The influence of oxime and anticholinergic drug selection on the potency of antidotal treatment to counteract acute toxic effects of tabun in mice.	2006-01	16464753
Role of cholinergic structures in individual resistance of rat circulatory system to posthemorrhagic hypoxia.	2005-08	16282994
Protection and inflammatory markers following exposure of guinea pigs to sarin vapour: comparative efficacy of three oximes.	2004-11-24	15558827
Acute experimental tabun-induced intoxication and its therapy in rats.	2004-03	15141977
Therapeutic efficacy of different antidotal mixtures against poisoning with GF-agent in mice.	2004	15841904
Anticholinergic drugs--functional antidotes for the treatment of tabun intoxication.	2004	15168875
Anticholinergic and antiglutamatergic agents protect against soman-induced brain damage and cognitive dysfunction.	2003-09	12832655
Neuroprotective efficacy of pharmacological pretreatment and antidotal treatment in tabun-poisoned rats.	2003-03-14	12505451
Effect of methoxime combined with anticholinergic, anticonvulsant or anti-HCN drugs in tabun-poisoned mice.	2003	14677719
A comparison of the neuroprotective efficacy of pharmacological pretreatment and antidotal treatment in soman-poisoned rats.	2003	14677718
A comparison of the efficacy of pyridostigmine alone and the combination of pyridostigmine with anticholinergic drugs as pharmacological pretreatment of tabun-poisoned rats and mice.	2002-08-15	12135621
The influence of anticholinergic drug and oxime selection on the effectiveness of antidotal treatment against tabun-induced poisoning in mice.	2002	12325456
Effects of advanced candidate anticonvulsants under two rodent models of 'counting'.	2001-12	11920930
Effects of selected anticholinergics on acoustic startle response in rats.	2001-12	11920928
[Effect of diazepam on antidote therapy of lethal toxic effects of soman in rats].	2001-09	11579693
[Effect of diazepam on the effectiveness of antidote therapy in eliminating the acute lethal effects of soman in mice].	2001-08	11678028
Inhibition effects of benactyzine and drofenine on human serum butyrylcholinesterase.	2001-02-01	11360997
The influence of anticholinergic drug selection on the effectiveness of oximes against soman-induced supralethal poisoning in mice.	2001	11488139
[The possible role of presynaptic effects in realizing the protective action of M-cholinolytics in dimethyl dichlorovinyl phosphate poisoning].	1991-07-01	1664807
[Effect of several neuroleptic, adreno-, sympatho- and cholinolytic substances on the development of experimental cerebral edema induced by nicotine].	1977-05-01	20324
Meprobamate-benactyzine (Deprol) and placebo in two depressed outpatient populations.	1969-03-01	4891208

Sample Use Guides

In Vivo Use Guide

The patient is receiving benactyzine at a dose starting with 1 mg three times a day rising within five days to 2 mg four times a day, and remaining at that level until the end of the test period

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:34:25 GMT 2025` Edited by `admin` on `Mon Mar 31 17:34:25 GMT 2025`
Record UNII	595EG71R3F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BENACTYZINE [HSDB]

Preferred Name

English

BENACTYZINE

Official Name

English

2-DIETHYLAMINOETHYL BENZILATE

Systematic Name

English

Benactyzine [WHO-DD]

Common Name

English

BENACTYZINE [VANDF]

Common Name

English

BENACTYZINE [MI]

Common Name

English

benactyzine [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29704